Literature DB >> 32833767

Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.

Klara Nilsson1,2, Fredrik Klevebro1,2, Ioannis Rouvelas1,2, Mats Lindblad1,2, Eva Szabo3, Ingvar Halldestam4, Ulrika Smedh5, Bengt Wallner6, Jan Johansson7, Gjermund Johnsen8, Eirik Kjus Aahlin9, Hans-Olaf Johannessen10, Geir Olav Hjortland11, Isabel Bartella12, Wolfgang Schröder12, Christiane Bruns12, Magnus Nilsson1,2.   

Abstract

OBJECTIVE: To investigate if prolonged TTS after completed nCRT improves postoperative outcomes for esophageal and esophagogastric junction cancer. SUMMARY OF BACKGROUND DATA: TTS has traditionally been 4-6 weeks after completed nCRT. However, the optimal timing is not known.
METHODS: A multicenter clinical trial was performed with randomized allocation of TTS of 4-6 or 10-12 weeks. The primary endpoint of this sub-study was overall postoperative complications defined as Clavien-Dindo grade II-V. Secondary endpoints included complication severity according to Clavien-Dindo grade IIIb-V, postoperative 90-day mortality, and length of hospital stay. The study was registered in Clinicaltrials.gov (NCT02415101).
RESULTS: In total 249 patients were randomized. There were no significant differences between standard TTS and prolonged TTS with regard to overall incidence of complications Clavien-Dindo grade II-V (63.2% vs 72.6%, P = 0.134) or regarding Clavien-Dindo grade IIIb-V complications (31.6% vs 34.9%, P = 0.603). There were no statistically significant differences between standard and prolonged TTS regarding anastomotic leak (P = 0.596), conduit necrosis (P = 0.524), chyle leak (P = 0.427), pneumonia (P = 0.548), and respiratory failure (P = 0.723). In the standard TTS arm 5 patients (4.3%) died within 90 days of surgery, compared to 4 patients (3.8%) in the prolonged TTS arm (P = 1.0). Median length of hospital stay was 15 days in the standard TTS arm and 17 days in the prolonged TTS arm (P = 0.234).
CONCLUSION: The timing of surgery after completed nCRT for carcinoma of the esophagus or esophagogastric junction, is not of major importance with regard to short-term postoperative outcomes.

Entities:  

Mesh:

Year:  2020        PMID: 32833767     DOI: 10.1097/SLA.0000000000004340

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  7 in total

Review 1.  Anaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy.

Authors:  M D Groenewold; C G Olthof; D J Bosch
Journal:  BJA Educ       Date:  2021-10-16

2.  The expression and clinical value of tumor infiltrating dendritic cells in tumor tissues of patients with esophageal cancer.

Authors:  Yanzhi Pei; Yanzhi Zhu; Xiaolin Wang; Lin Xu
Journal:  J Gastrointest Oncol       Date:  2021-10

3.  Continuously sutured versus linear-stapled anastomosis in robot-assisted hybrid Ivor Lewis esophageal surgery following neoadjuvant chemoradiotherapy: a single-center cohort study.

Authors:  Fiorenzo V Angehrn; Kerstin J Neuschütz; Daniel C Steinemann; Martin Bolli; Lana Fourie; Pauline Becker; Markus von Flüe
Journal:  Surg Endosc       Date:  2022-07-19       Impact factor: 3.453

Review 4.  Neoadjuvant Therapy for Locally Advanced Esophageal Cancers.

Authors:  Runkai Huang; Zhenbin Qiu; Chunwen Zheng; Ruijie Zeng; Wanxian Chen; Simeng Wang; Enmin Li; Yiwei Xu
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

Review 5.  Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction.

Authors:  Yi-Han Zheng; En-Hao Zhao
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

6.  Peri-anastomotic microdialysis lactate assessment after esophagectomy.

Authors:  Jakob Hedberg; Gustav Linder; Magnus Sundbom
Journal:  Esophagus       Date:  2021-05-29       Impact factor: 4.230

7.  Photon Versus Proton Beam Therapy for T1-3 Squamous Cell Carcinoma of the Thoracic Esophagus Without Lymph Node Metastasis.

Authors:  Yang-Gun Suh; Unurjargal Bayasgalan; Heung Tae Kim; Jong Mog Lee; Moon Soo Kim; Youngjoo Lee; Doo Yeul Lee; Sung Uk Lee; Tae Hyun Kim; Sung Ho Moon
Journal:  Front Oncol       Date:  2021-06-21       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.